Drug Trial News

RSS

Boehringer Ingelheim completes enrollment in nintedanib Phase III trials for IPF

Boehringer Ingelheim is pleased to announce the last patients have been randomised into the Phase III sister trials assessing the efficacy and safety of nintedanib (150 mg twice daily) in patients with idiopathic pulmonary fibrosis (IPF).

24 Sep 2012

Denosumab effective in treating giant-cell tumor of the bone

Treatment with denosumab, a drug targeted against a protein that helps promote bone destruction, decreased the number of tumor giant cells in patients with giant-cell tumor of the bone, and increased new bone formation, according to the results of a phase II study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

24 Sep 2012

Radioactive iodine should only be used in treatment of some patients with papillary thyroid cancer

Radioactive iodine should only be used in the treatment of some patients with papillary thyroid cancer, according to data presented at the 82nd Annual Meeting of the American Thyroid Association (ATA) in Québec City, Québec, Canada.

24 Sep 2012

EMA CHMP adopts positive opinion for ELIQUIS to prevent stroke, systemic embolism in NVAF patients

Bristol-Myers Squibb and Pfizer Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending that ELIQUIS (apixaban) be granted approval for the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) and one or more risk factors for stroke.

21 Sep 2012

Study finds drug may aid some autism patients

An experimental drug can improve sociability in patients with fragile X syndrome and may be helpful as a treatment for autism, according to the authors of a new study.

21 Sep 2012

Radioactive iodine may predispose young thyroid cancer patients to second primary malignancies

Children and young adult thyroid cancer patients who are treated with radioactive iodine have an elevated risk of developing a second primary malignancy, according to new data presented at the 82nd Annual Meeting of the American Thyroid Association in Québec City, Québec, Canada.

21 Sep 2012

ChromaDex announces findings from pTeroPure Phase 2/3 trial on high blood pressure

ChromaDex Corporation announced today findings from a Phase 2/3 trial at the University of Mississippi Medical Center showing its patented nutritional ingredient pTeroPure (pterostilbene) significantly reduced blood pressure in adults.

21 Sep 2012

Data from Navidea’s Lymphoseek Phase 3 studies on solid tumors to be presented at ESSO

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its completed Phase 3 Lymphoseek studies in breast cancer and melanoma are being presented at the 32nd Congress of the European Society of Surgical Oncology (ESSO) in Valencia, Spain, from September 19-21, 2012.

21 Sep 2012

Medivir’s simeprevir and TMC647055 to enter phase IIa combination trial for HCV genotype-1

Medivir AB, announced today that simeprevir (TMC435) and TMC647055, a non-nucleoside inhibitor (NNI) will enter a phase IIa interferon free combination trial.

21 Sep 2012

Positive results from Galleon GAL-021 second Phase I study on respiratory depression

Galleon Pharmaceuticals, a leader in the development of novel medicines to treat breathing control disorders, today announced that results from a second Phase I clinical study of its investigational drug GAL-021 confirmed previous findings that the drug has dose-dependent effects on respiration.

21 Sep 2012

Cytochroma commences CTAP101 phase 3 study in secondary hyperparathyroidism

Cytochroma today announced the initiation of a phase 3 study of CTAP101 capsules in patients with secondary hyperparathyroidism (SHPT), stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

21 Sep 2012

Lund University professor to coordinate oral insulin study for type 1 diabetes

Type 1 diabetes is the autoimmune form of diabetes, in which the patients' insulin-producing beta cells are destroyed by their own immune system. "We know that if a person has two autoantibodies and one of them is against insulin, there is a 50 per cent risk that they will develop type 1 diabetes within five years. It doesn't matter how old you are", says Ake Lernmark, Professor of Experimental Diabetes Research at Lund University in Sweden.

20 Sep 2012

Aerpio Therapeutics commences AKB-9778 Phase 1b/2a trial in diabetic macular edema

Aerpio Therapeutics, a clinical-stage biopharmaceutical company developing innovative therapies for vascular diseases by targeting the Tie2 pathway, today announced that it has dosed the first patient in a Phase 1b/2a trial of AKB-9778 for the treatment of diabetic macular edema (DME).

20 Sep 2012

APR-246 can restore function of defective p53 and activate apoptosis in cancer cells

The p53 gene plays a key role in the prevention of cancer, by blocking cell growth and triggering programmed cell death or apoptosis. If, however, p53 has mutated and become defective, the cancer cells can acquire the ability to evade apoptosis and become more resistant to therapy.

20 Sep 2012

FDA Division of Neurology Products, CoLucid reach agreement for lasmiditan development strategy

CoLucid Pharmaceuticals, Inc., a privately held biopharmaceutical company, has reached agreement with the Food and Drug Administration's Division of Neurology Products concerning the development strategy for lasmiditan at a recently completed End of Phase 2 meeting.

19 Sep 2012

Positive data from Nektar’s NKTR-192 Phase 1a study on acute pain

Nektar Therapeutics announced today that positive data from the first single-ascending dose Phase 1a clinical study of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate, demonstrate that the drug candidate achieved its target pharmacokinetic profile.

19 Sep 2012

Navidea commences enrollment in [18F]NAV4694 Phase 2 study for Alzheimer's

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that enrollment has commenced at two sites participating in its Phase 2, open-label, safety and efficacy PET imaging study of [18F]NAV4694 for detection of cerebral β-amyloid plaque in subjects diagnosed with probable Alzheimer's disease (AD).

19 Sep 2012

Abiraterone acetate confirmed to offer significant survival benefit to advanced prostate cancer patients

Results of a phase 3 trial published in The Lancet Oncology have confirmed that the drug abiraterone acetate (marketed as Zytiga®) offers a significant survival benefit to patients with castration-resistant prostate cancer, which is spreading to other parts of their body (known as metastatic prostate cancer).

18 Sep 2012

Pfizer announces that 14 abstracts for tofacitinib to be presented at ACR/ARHP annual meeting

Pfizer Inc. announced today that 14 abstracts for tofacitinib, an investigational oral Janus kinase (JAK) inhibitor for the treatment of adults with moderate-to-severe active rheumatoid arthritis (RA), will be presented at the American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) 2012 Annual Meeting, which is being held November 9-14 in Washington, D.C.

18 Sep 2012

Thalidomide effective in treating disabling cough among people with idiopathic pulmonary fibrosis

In the first clinical trial to demonstrate an effective treatment for constant, disabling cough among people with idiopathic pulmonary fibrosis (IPF), researchers at the Johns Hopkins University School of Medicine found that taking thalidomide significantly reduced the cough and improved quality of life.

18 Sep 2012

Drug Trial News

Boehringer Ingelheim completes enrollment in nintedanib Phase III trials for IPF

Denosumab effective in treating giant-cell tumor of the bone

Radioactive iodine should only be used in treatment of some patients with papillary thyroid cancer

EMA CHMP adopts positive opinion for ELIQUIS to prevent stroke, systemic embolism in NVAF patients

Study finds drug may aid some autism patients

Radioactive iodine may predispose young thyroid cancer patients to second primary malignancies

ChromaDex announces findings from pTeroPure Phase 2/3 trial on high blood pressure

Data from Navidea’s Lymphoseek Phase 3 studies on solid tumors to be presented at ESSO

Medivir’s simeprevir and TMC647055 to enter phase IIa combination trial for HCV genotype-1

Positive results from Galleon GAL-021 second Phase I study on respiratory depression

Cytochroma commences CTAP101 phase 3 study in secondary hyperparathyroidism

Lund University professor to coordinate oral insulin study for type 1 diabetes

Aerpio Therapeutics commences AKB-9778 Phase 1b/2a trial in diabetic macular edema

APR-246 can restore function of defective p53 and activate apoptosis in cancer cells

FDA Division of Neurology Products, CoLucid reach agreement for lasmiditan development strategy

Positive data from Nektar’s NKTR-192 Phase 1a study on acute pain

Navidea commences enrollment in [18F]NAV4694 Phase 2 study for Alzheimer's

Abiraterone acetate confirmed to offer significant survival benefit to advanced prostate cancer patients

Pfizer announces that 14 abstracts for tofacitinib to be presented at ACR/ARHP annual meeting

Thalidomide effective in treating disabling cough among people with idiopathic pulmonary fibrosis

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News